Amir Kalali, M.D., former global head of Quintiles (now IQVIA) neuroscience center of excellence, provides insight on why he decided to found an educational conference, The CNS Summit, while still working as a biopharmaceutical industry executive.
What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.
A primer on AI terminology for the upcoming August feature with Sanofi’s Medical Function EVP, Ameet Nathwani, M.D.
An op-ed regarding Pfizer’s drug-pricing actions, President Trump, and the potential impact on the biopharmaceutical industry’s image.
A review of buzzwords and phrases that should be used less in the world of business.
BIO 2018 does more than make business meeting history, but facilitates personal connections that can lead toward doing better business.
Miriam Massaad, a biomedical engineering student at Boston University, shares her experiences as a first-time attendee at the 2018 BIO International Convention and Conference in Boston.
Robert Coughlin, president and CEO of MassBio, discusses his organization’s approach to diversity and inclusion.
Dave Thomas, managing director for industry research and analysis at the Biotechnology Innovation Organization (BIO), discusses chronic disease research and other industry trends.
Shaness Grenald, Ph.D., a postdoctoral fellow in the department of anesthesiology and critical care medicine at Johns Hopkins University, discusses the Scientist Mentoring and Diversity Program (SMDP) at the 2018 BIO Buzz Center in Boston.
|
|
|
|
|
|
|
|
|